• Reference companies may lower drug prices too • Payers may mandate biosimilar use in tender markets • Immunogenicity reactions...

Biopharmaceutical Report III Goodwill Hunting Martin Shkreli and Hillary Clinton last week provided the flint and steel that ignited a...

• Success in vitro foreshadows pan-genotypic success • Six HCV genotypes have unique viral dynamics • Drug should be bearable for...

PARP inhibitors like Tesaro’s (NASDAQ:TSRO) niraparib, Clovis Oncology’s (NASDAQ:CLVS) rucaparib and AstraZeneca’s (LON:AZN) approved...

Competing in gene therapy is unlikely to follow the same rules as competing in other therapeutic categories where — even in Orphan...

Seattle Genetics (NASDAQ:SGEN) and Takeda Pharmaceutical’s (TYO:4502) Adcetris (brentuximab vedotin) will likely get a Hodgkin’s lymphoma...

Rheumatologists in the US eagerly anticipate biosimilars for pricey anti-TNFs and other biologics used to treat rheumatic diseases but...

Featured Story of Korean Pharma: Hanwha confirms abandoning bid for Dow Chemical basic chemical units Hanwha Corp is no longer seeking to...

Astellas (TYO:4503)/Medivation's (NASDAQ:MDVN) Phase II TERRAIN study topline data on Xtandi has left experts questioning whether it will...

Spark Therapeutics' (NASDAQ:ONCE) subretinal gene therapy injection of SPK-RPE65, is likely to restore vision most effectively in younger...